Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O00443
UPID:
P3C2A_HUMAN
Alternative names:
Phosphoinositide 3-kinase-C2-alpha
Alternative UPACC:
O00443; B0LPH2; B4E2G4; Q14CQ9
Background:
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha, also known as Phosphoinositide 3-kinase-C2-alpha, plays a pivotal role in cellular processes including insulin signaling, glucose uptake, and vesicle trafficking. It generates crucial second messengers, PtdIns3P and PtdIns(3,4)P2, influencing various intracellular pathways.
Therapeutic significance:
Linked to Oculoskeletodental syndrome, this protein's dysfunction reveals its critical role in human health. Understanding the role of Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha could open doors to potential therapeutic strategies for this and related disorders.